New York, May 28, 2026, 05:04 EDT
- Arcadia Biosciences’ stock was last quoted at $0.925, up 1.25%, valuing the company at about $1.9 million.
- U.S. equity markets are scheduled for a regular session; Nasdaq’s 2026 calendar lists the Memorial Day closure on May 25 and the next full closure on June 19.
- Arcadia’s latest company release remains its May 14 first-quarter report; its investor site lists a Schedule 13G filing dated May 15 as the newest filing.
Arcadia Biosciences Inc. shares were quoted higher but still below $1 early Thursday, leaving the micro-cap wellness-products company in a narrow market lane where small changes in cash, sales or financing can move the stock. Micro-cap means a company with a very small market value; Arcadia’s was about $1.9 million at the latest quote.
Why it matters now: there was no newer operating release on Arcadia’s investor-relations feed after its May 14 results, and the latest listed company filing was May 15. That puts the focus back on what the last filing cycle showed — Zola coconut water growth on one side, funding pressure on the other.
Arcadia said first-quarter Zola unit volumes rose 18% from a year earlier and selling, general and administrative expenses, or SG&A — overhead costs such as staff, professional fees and sales commissions — fell to the lowest level in its history as a public company. Chief Executive T.J. Schaefer said the company was “very pleased” with the quarter and remained focused on “growing our Zola coconut water brand.” Arcadia Biosciences, Inc.
The numbers were less clean. Revenue fell 8% to $1.1 million, operating expenses rose to $1.9 million, and Arcadia posted a net loss to common shareholders of $4.4 million, or $2.11 a share, compared with net income of $2.6 million a year earlier.
The company said the revenue drop mainly reflected a reserve release booked in 2025 that did not repeat in 2026, while the loss was tied in part to a January inducement offer. An inducement offer is a deal that encourages holders of warrants or similar rights to buy shares, often by changing terms.
Arcadia has become largely a Zola story. Its 10-Q said product revenue consisted primarily of Zola sales, and that the brand is sold through grocery retailers and foodservice distributors across the United States.
That puts it in a hot but crowded pocket of beverages. Larger rival Vita Coco reported first-quarter net sales of $180 million, up 37%, driven by 42% growth in Vita Coco Coconut Water, and raised its 2026 revenue guidance to $720 million-$735 million. Michael Kirban, Vita Coco’s co-founder and executive chairman, called the start to 2026 “exceptional.” The Vita Coco Company
The wider tape was supportive. Wall Street’s main indexes closed at record highs on Wednesday, with the Nasdaq up 0.07% and the S&P 500 up 0.02%, Reuters reported, as gains in healthcare and consumer stocks offset weaker energy and some chip names.
But the risk case is still stark. Arcadia’s 10-Q said it had $1.0 million of cash and cash equivalents at March 31, used $1.1 million in operations during the quarter, and had “substantial doubt” about its ability to continue as a going concern, meaning whether it can keep operating without more money. The company said any equity raise would dilute holders; dilution means existing investors own a smaller share after new stock is issued. SEC
The week ahead is therefore likely to turn on disclosure, not broad market mood. Traders will look for any filing, financing update, Zola distribution news or sign that Arcadia can stretch its cash while keeping the brand growing.
